MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

Search

Allogene Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.15 -1.71

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.13

Max

1.21

Pagrindiniai rodikliai

By Trading Economics

Pajamos

206K

-60M

Pelnas, tenkantis vienai akcijai

-0.28

Pelno marža

272,450

Darbuotojai

226

EBITDA

-302K

-56M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+637.82% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

2.2M

258M

Ankstesnė atidarymo kaina

2.86

Ankstesnė uždarymo kaina

1.15

Naujienos nuotaikos

By Acuity

50%

50%

113 / 375 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Allogene Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-06 23:55; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Position Adjustments -- Market Talk

2025-07-06 22:35; UTC

Įsigijimai, susijungimai, perėmimai

South32 Expects to Complete Transaction in Late 2025

2025-07-06 22:35; UTC

Įsigijimai, susijungimai, perėmimai

South32: CoreX to Make Future Cash Payments of Up to US$100 Million for Cerro Matoso

2025-07-06 22:34; UTC

Įsigijimai, susijungimai, perėmimai

South32 Agrees to Sell Cerro Matoso Nickel Operation to Unit of CoreX Holding

2025-07-05 04:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-04 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-04 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-07-04 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-07-04 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2025-07-04 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-04 16:20; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2025-07-04 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-07-04 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-07-04 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-04 15:57; UTC

Rinkos pokalbiai

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

2025-07-04 15:49; UTC

Rinkos pokalbiai

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

2025-07-04 15:49; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

2025-07-04 15:49; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

2025-07-04 15:49; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Received All Required Authorizations

2025-07-04 15:48; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

2025-07-04 15:47; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: Agreement Was Announced on Dec. 19

2025-07-04 15:47; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

2025-07-04 15:46; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

2025-07-04 14:30; UTC

Įsigijimai, susijungimai, perėmimai

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

2025-07-04 13:53; UTC

Rinkos pokalbiai

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

2025-07-04 13:41; UTC

Rinkos pokalbiai

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

2025-07-04 13:41; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-07-04 13:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-04 12:37; UTC

Rinkos pokalbiai

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

2025-07-04 12:37; UTC

Rinkos pokalbiai

Fund Manager Roundup: U.S. Treasurys in Focus -2-

Akcijų palyginimas

Kainos pokytis

Allogene Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

637.82% į viršų

12 mėnesių prognozė

Vidutinis 8.78 USD  637.82%

Aukščiausias 14 USD

Žemiausias 4 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Allogene Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

11

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.18 / 1.69Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

113 / 375 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.